相关实验视频
Updated: Sep 13, 2025

09:41
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
Published on: July 19, 2019
11.6K
与认知衰退相关的ARSA变体和在元色性白血病中长期保持运动功能的ARSA变体
Shanice Beerepoot1,2,3, Daphne H Schoenmakers1,2,4, Francesca Fumagalli5,6,7
1Amsterdam Leukodystrophy Center, Department of Child Neurology, Emma Children's Hospital, Amsterdam UMC, Location Vrije Universiteit, Amsterdam, the Netherlands.
Journal of inherited metabolic disease
|August 2, 2025
概括
具有特定ARSA变异的甲基色白血病 (MLD) 患者通常会经历认知衰退而不是运动问题. 早期干预,如造血干细胞移植 (HSCT),可以保持运动功能和认知能力.
科学领域:
- 神经学 神经学
- 遗传学 遗传学 是一个
- 生物化学 生物化学
背景情况:
- 甲染色白血病 (MLD) 是一种罕见的遗传疾病,其特征是神经系统逐渐恶化.
- 在ARSA基因中的特定变异,包括c.256C>T,c.257G>A和c.542T>G,与MLD表型有关.
- 患有MLD的患者表现可以从运动到认知能力下降,需要对基因型-表型相关性进行详细分析.
研究的目的:
- 分析发病类型,临床表现,认知和运动功能,中枢运动道干扰,MRI严重程度,外围神经病变以及特定ARSA变异患者的存活率.
- 评估血造干细胞移植 (HSCT) 对疾病进展和患者结局的影响.
- 建立基因型-表型相关性,并确定ARSA变异型的MLD患者的最佳治疗结果.
主要方法:
- 多国性研究涉及47名患有MLD和确定的ARSA变体 (c.256C>T,c.257G>A,c.542T>G) 的患者.
- 综合性评估包括发病类型,临床症状/征兆,认知功能,毛细运动功能,中部运动道成像,MRI严重性评分,外围神经病变评估和生存数据.
- 对接受血造干细胞移植 (HSCT) 患者与未接受治疗的患者进行分析.
主要成果:
- 晚年青少年 (46.8%) 和成人 (44.7%) 发病最常见,主要是认知能力下降 (40/41例有症状的患者).
- 没有接受治疗的患者通常会保持独立行走 (100%),节省中央运动道 (87.5%),并且没有脱髓神经病变 (95.5%).
- 与未接受治疗的患者相比,HSCT接受者通常保持了独立行走和正常的认知功能,MRI严重程度的中位数得分较低.
结论:
- 与c.256C>T ARSA变异相关的表型受到同时发生变异的严重程度的影响.
- 患有c.257G>A或c.542T>G变异的患者通常表现出晚年青春期/成年期发病,认知能力下降,并保留了中央运动通道的运动功能.
- 认知功能和MRI严重性得分是MLD患者治疗结果的关键指标,患者有c.257G>A或c.542T>G变异.
相关概念视频
Lysosomal Hydrolases
3.9K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.9K
Parkinson's Disease: Overview
708
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
708

